Participating Companies

Affibody
Lead candidate Izokibep, supported by partnership with Acelyrin, is an IL-17 inhibitor with multiple Ph2 programs in progress (PSO, axSpA, uveitis, HS, PsA). ACR50 primary endpoint met for 16 wk data in PsA. First patient dosed in pivotal Phase 2b trial for uveitis filed in 1H2022 with 24 wk data expected in 2023. [more information]

Affimed
[AFMD]
$73 MM MCap
Oncology therapeutics developer with most advanced AFM13 for r/r peripheral T-cell lymphoma completing Ph2 enrollment. AFM24 for multiple solid tumors is in Ph 2a as monotherapy. [more information]

Agiliti Health
[AGTI]
$877 MM MCap
healthcare industry with solutions that help support a more efficient, safe and sustainable healthcare delivery system. Agiliti serves more than 9,000 national, regional and local acute care and alternate site providers across the U.S. For more than eight decades, Agiliti has delivered medical equipment management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes. [more information]

Akili
[AKLI]
$41 MM MCap
Prescription digital therapeutics company (PDT) with EndeavorRx, the first FDA-cleared video game treatment option for ADHD (pediatric patients). The company set commercial launch for EndeavorRx for 2H 2022. Akili has projected $500M in sales potential for EndeavorRx for the US ADHD market achievable within 5-7 years post-launch. [more information]

Alladapt
Developing a potentially best-in-class oral immunotherapy that addresses a broad range of food allergies. ADP101, which is in a Ph 1/2 study and an OLE study, is designed to desensitize patients allergic to one or to multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions. The Company was co-founded by Dr. Kari Nadeau, a renowned food allergist, and former 23andMe exec, Ashley Dombkowski who serves is CEO. Data from Ph 1/2 study expected 1Q23. [more information]

Arbor Biotechnologies
With the most extensive library of CRISPR nucleases in the industry, a deep bench of world-class founders, scientific advisors, and a leadership team with a proven track record of developing novel platforms and therapeutics, Arbor is well-positioned to develop curative genetic medicines for all patients with genetic diseases. Arbor’s pipeline is powered by its proprietary biodiscovery engine, which blends computational search and scientific expertise to discover, screen, and engineer proteins at unprecedented scale and speed. Arbor has raised more than $300 million to date and top investors include ARCH Venture Partners, Temasek, Ally Bridge Group, and TCG Crossover. [more information]

Arbutus Biopharma
[ABUS]
$322 MM MCap
To address HBV, developing a RNAi therapeutic, an oral PD-L1 inhibitor, and oral RNA destabilizer and intend to combine with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. AB-729, is potentially the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. [more information]

AxoGen
[AXGN]
$215 MM MCap
Leading company focused on development and commercialization of technologies for peripheral nerve regeneration and repair. Lead product Avance Nerve graft is biologically-active OTS human allograft. FY 2022 revenue guidance of $135-$142M represents 10%-15% YOY growth ex. $4.1M from discontinued Avive revenue. [more information]

Bavarian Nordic A/S
[BAVA]
Global leader in vaccines for infectious diseases. Commercial products include the world’s only approved monkeypox vaccine and market-leading vaccines against rabies, tick-borne encephalitis, in addition to an Ebola vaccine licensed to Janssen. Company delivered more than 4 million doses of monkeypox vaccines in 2022 covering more than 70 countries and expects to supply ~10 million doses through 2023. Enrollment is ongoing in global Ph 3 COVID booster trial and global Ph 3 RSV trial with access to accelerat [more information]

BenevolentAI
[BAI]
Combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. The unique computational R&D platform spans every step of the drug discovery process, powering a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, maintaining successful collaborations. [more information]

Benitec Biopharma
[BNTC]
$5 MM MCap
Their lead candidate BB-301 in OPMD has achieved mechanistic and therapeutic proof of concept in two pre clinical animal models. A natural history study to collect baseline data in OPMD patients necessary for a clinical trial is ongoing, with the IND clearance expected in 2Q23. [more information]

Bexion Pharmaceuticals
A clinical-stage biopharmaceutical company developing a new generation of biologic immunotherapy to treat Solid Tumor Cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN). Bexion's lead asset BXQ-350 activates Sphingoloid Metabolism and has demonstrated excellent safety and monotherapy benefits across multiple tumor types in its completed adult and pediatric Ph 1 study. Ph 2 study in CRC expected 4Q22. The Company has $80M raised to date. [more information]

CellMax Life
Private liquid biopsy company dedicated to transforming how cancer is detected and managed with globally affordable non-invasive blood tests for early cancer detection and monitoring.
The company is currently focused on colorectal cancer (CRC) screening using the clinically validated FirstSight (TM), a blood biopsy test that detects pre-cancerous lesions (adenomas) in as little as two teaspoons of blood (less than 10mL). FirstSight is marketed for regular testing in patients 45 years and older. [more information]

Compass Pathways
[CMPS]
$313 MM MCap
Mental health company focused on psilocybin therapy in conjunction with psychological support, with FDA Breakthrough Therapy designation for lead asset COMP360 in treatment-resistant depression. Top-line Ph 2b data showed significant improvements in depressive symptoms, Ph 3 to commence in Q4 '22. Add'l Ph 2 trials in PTSD and anorexia nervosa ongoing. [more information]

Corium
Commercial-stage neuroscience company leading development and commercialization of neuroscience therapies. Two FDA-approved drugs AZSTARYS (ADHD) and ADLARITY (Alzheimer's Disease) represent combined peak sales potential in excess of >$1B. [more information]

CureVac
[CVAC]
$1,529 MM MCap
In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. [more information]

Delcath Systems, Inc.
[DCTH]
$62 MM MCap
Interventional oncology company focused on the treatment of primary and metastatic liver cancers. Company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the U.S., the PHP system is being developed under the tradename HEPZATO KIT or HEPZATO, and is considered a combination drug and device product regulated by the FDA. [more information]

DURECT
[DRRX]
$63 MM MCap
Lead compound, larsucosterol, granted FDA Fast Track Designation for alcohol-associated hepatitis (AH), resulted in 100% 28-day survival for AH patients in a Phase IIa study, with Phase IIb trial enrollment completion anticipated 2Q23. [more information]

ESSA Pharma
[EPIX]
$136 MM MCap
Developing novel therapies for the treatment of prostate cancer targeting the N-terminal domain of the androgen receptor. ESSA’s lead clinical candidate, EPI-7386 is a highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor in development as a monotherapy (Ph 1) and in combination with standard-of-care antiandrogens in patients with castration-resistant prostate cancer (Ph 1/2). [more information]

Galera
[GRTX]
$8 MM MCap
Clinical stage biopharmaceutical company transforming radiotherapy in cancer. Lead asset avasopasem is a potent, highly selective small molecule dismutase mimetic being developed for severe oral mucositis (SOM). Topline Ph 3 data announced in 4Q21, with NDA submission expected by the end of 2022. Completion of enrollment for second asset rucosapasem in two anti-cancer studies is expected 2H23. [more information]

GENFIT
[GNFT]
$163 MM MCap
Development programs addressing rare and severe liver diseases. Ph3 data for elafibranor in primary biliary cholangitis (PBC) ELATIVE study, expected 2Q23. Acquisition of Versantis brings VS-01-ACLF, a Ph2 ready program for severe liver disease. Licensing and development agreement with IPSEN began December 2021. [more information]

Geron
[GERN]
$1,110 MM MCap
Late-stage biopharmaceutical company pursuing therapies for patients with hematologic malignancies. First-in-class telomerase inhibitor, imetelstat, in two Ph3 pivotal clinical trials in lower risk myelodysplastic syndromes (LR MDS; top-line data early Jan 2023), and in relapsed/refractory myelofibrosis (MF). [more information]

HUTCHMED
[HCM]
$2,930 MM MCap
NASDAQ, AIM and Hong Kong-listed global commercial-stage oncology company with 3 approved and marketed targeted cancer drugs in China and plans for regulatory submissions in the US, EU and Japan in 2023. Key partnerships with Eli Lilly, AstraZeneca and BeiGene. [more information]

ImmuneSensor
A private, clinical stage therapeutic innate immunity company developing drugs targeting the cGAS-STING pathway for the treatment of cancer and autoimmune diseases. The company was co-founded by Dr. Zhijian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the discovery of the cGAS-STING pathway. The company pipeline includes a clinical stage STING agonist, currently in monotherapy and ICI combination trial, with expectations to enter Phase 2 in 2H23. [more information]

Immunocore
[IMCR]
$2,334 MM MCap
A pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, with the first TCR therapeutic to receive regulatory approval. [more information]

KBio
Creating the new generation of biologics using its plant-based platform that has demonstrated an ability to create potentially better drug candidates at a fraction of the time and cost of conventional platforms. Focused on discovering monoclonal antibodies targeting validated pathways for rare and infectious diseases and, due to the speed and accuracy of its antibody production system, is positioned well to develop fast follower therapies against validated drug targets. [more information]

Keros Therapeutics
[KROS]
$915 MM MCap
A leader in understanding the role of the TGF-Beta family of proteins that is a master regulator of RBC and platelet production as well as the growth, repair and maintenance of muscle and bone. Lead protein therapeutic product candidate, KER-050, being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with MDS and MF. KER-012 is being developed for the treatment of PAH and for the treatment of disorders associated with bone loss. [more information]

Kezar Life Sciences
[KZR]
$76 MM MCap
Clinical stage biotechnology company pioneering first-in-class, small molecule therapies by targeting key intracellular proteins. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors. [more information]

Longboard Pharmaceuticals
[LBPH]
$113 MM MCap
Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. The company is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2). [more information]

Marker Therapeutics
[MRKR]
$39 MM MCap
Focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. [more information]

MiNA Therapeutics
Leader in RNA activation (RNAa). Technology capable of drugging any protein target to increase natural protein production in patients own cells. Immuno-oncology and rare disease pipeline with 10 clinical assets expected by 2025 and first FDA approval in 2024. Key programs include MTL-CEPBA (ongoing randomized Ph2 in 2L HCC, Ph1/1b in advanced solid tumors resistant to anti-PD1), MTL-STING, monogeneic rare disease programs. $1.5B+ pharma partnerships. [more information]

Minerva Biotechnologies
A clinical stage biopharmaceutical company developing cancer immunotherapies and drugs to target 75% of solid tumors and to prevent cancer metastasis. Minerva has a pipeline that includes next-gen CAR Ts and other modalities. The Company has an ongoing Phase I/II study of huMNC2-CAR44, an autologous CAR T therapy, targeting the tumor-associated form of MUC1 (MUC1*) which is a growth factor receptor that drives growth of an estimated 93% of breast cancers. [more information]

Monte Rosa Therapeutics
[GLUE]
$224 MM MCap
Multi-asset next-gen AI-driven molecular glue-based TPD platform. Lead program in Ph 1 focused on GSPT1, a key regulator and vulnerability of MYC-driven solid tumors, including lung cancer. [more information]

NexImmune
[NEXI]
$5 MM MCap
Developing unique approaches to T cell immunotherapies based on its proprietary, multi-antigen Artificial Immune Modulation (AIM™) technology. AIM™ technology employs natural biology to direct specific T cell-mediated immune responses capable of treating a variety of cancers and autoimmune diseases. Ongoing Phase I/II in R/R AML with data expected around YE22. Initiating a Phase I/II in HPV-mediated solid tumors. Autoimmune programs advancing quickly. [more information]

NorthSea Therapeutics
Focused on developing SEFAs for the treatment of NASH and other metabolic disorders. Phase 2b ICONA NASH trial icosabutate showed significant decreases in NASH and fibrotic biomarkers and is scheduled to readout biopsy data in 1Q23. Two additional SEFAs (1024 and 6179) in Phase 1 clinical trials for patients with dyslipidemia and the orphan indication IFALD, respectively. [more information]

Nykode Therapeutics
[NYKD]
Clinical stage immunotherapy company focused on cancer and infectious disease. Modular vaccine technology targets antigens to Antigen Presenting Cells to achieve rapid, strong and long-lasting immune responses. Key programs include Ph2 proprietary HPV 16+ cervical cancer therapeutic vaccine, Ph1/2 individualized cancer neoantigen vaccine (Genentech). Significant collaborations with Regeneron and Genentech. [more information]

Pharming Group
[PHAR]
$759 MM MCap
Building a sustainable rare disease business, preparing for approval/launch of leniolisib for APDS. Revenues >$200M (TTM) from Ruconest (marketed) for the treatment of acute hereditary angioedema (HAE) attacks including breakthrough attacks. Leniolisib, a targeted PI3Kδ inhibitor initially being developed for PI3K delta syndrome (APDS), is on track to be the first approved disease-modifying treatment for APDS, a rare genetic immunodeficiency, in Q1 2023 (FDA) and H1 2023 (EMA). Dual listed on Nasdaq.
[more information]

Photocure
[PHCUF]
$136 MM MCap
Lead product Hexvix®/Cysview® improves detection of bladder cancer under blue light cystoscopy (BLC). Approved in over 30 countries, Hexvix®/Cysview® is directly sold in the US and EU, and through worldwide partnerships. Photocure expects up to $250M from license of non-core asset CEVIRA® to Asieris. Headquartered in Oslo, Norway, Photocure is 20% owned by US investors (significant increase over past few years) and commercially focused on US market. [more information]

Pieris Pharmaceuticals
[PIRS]
$28 MM MCap
Lead program (AZN-partnered) PRS-060, is an inhaled IL4Ra inhibitor for moderate-to-severe asthma, with Phase 2 topline data expected by 3Q23; Phase 1/2 enrollment continues for Servier-partnered PRS-344 (4-1BB/PD-L1 bispecific) for solid tumors. [more information]

Redx Pharma
[REDX]
Lead fibrosis asset, the selective ROCK2 inhibitor RXC007, is in development for lung fibrosis, with Ph2a topline data for idiopathic pulmonary fibrosis expected H223. Lead oncology asset, Porcupine inhibitor RXC004, for Wnt dependent cancers, Ph2 topline data expected starting in H123 and into H223. RXC008, a GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease, is in pre-IND stage, commencing Ph1 clinical studies in late 2023. [more information]

Sonnet Biotherapeutics
[SONN]
$5 MM MCap
Clinical-stage multi-asset immuno-oncology therapeutics platform company featuring proprietary technology improving in vivo half-life and tumor tissue specificity of interleukins. SON-1010 (IL-12-FHAB) in phase I SAD and SON-080 (low dose IL-6) in phase 1b/2a. [more information]

Spruce Biosciences
[SPRB]
$92 MM MCap
Focused on developing and commercializing novel therapies for rare endocrine disorders. The company’s lead product candidate, Tildacerfont, is currently being evaluated for the treatment of classic adult congenital adrenal hyperplasia (CAH), and in upcoming studies in pediatric classic CAH and Polycystic Ovary Syndrome (PCOS). [more information]

Sutro Biopharma
[STRO]
$185 MM MCap
Clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. STRO-003, an optimally designed ROR1-targeting ADC, is anticipated to be the next proprietary product candidate to move into clinical studies. [more information]

Treos Bio
Develops precision peptide cancer immunotherapies using patient HLA target recognition genetics based on proprietary computational data science. Treos’ lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a biomarker-based Phase 1b clinical trial. Treos has raised $42 million to date. [more information]

XWPharma
Focused on providing potential first- and best-in-class medicines for patients suffering from debilitating neurological diseases. XW10172 is a clinical-stage conjugate of the GABAB agonist, oxybate, in development as an investigational once-nightly therapy intended to regulate the patient’s sleep cycle in Parkinson's disease and narcolepsy. XW10508 is a glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for major depressive disorder and chronic pain. [more information]

Zentalis
[ZNTL]
$1,402 MM MCap
Developing best-in-class small molecule therapeutics targeting fundamental biological cancer pathways. Lead candidates are ZN-c3, a Wee1 inhibitor for advanced solid tumors and ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders. Multiple mono and combo trials are ongoing/planned across the pipeline. [more information]